Sernova – Patentierte Zelltaschen mit Schutzschild gegen die Immunabwehr ! (Seite 3)
eröffnet am 24.06.15 16:59:24 von
neuester Beitrag 05.06.24 11:17:27 von
neuester Beitrag 05.06.24 11:17:27 von
Beiträge: 8.646
ID: 1.214.676
ID: 1.214.676
Aufrufe heute: 4
Gesamt: 1.087.307
Gesamt: 1.087.307
Aktive User: 0
ISIN: CA81732W1041 · WKN: A0LBCR · Symbol: SVA
0,2555
EUR
+3,23 %
+0,0080 EUR
Letzter Kurs 05.06.24 L&S Exchange
Neuigkeiten
| TitelBeiträge |
|---|
30.05.24 · Shareribs Anzeige |
29.05.24 · wO Chartvergleich |
28.05.24 · Shareribs Anzeige |
28.05.24 · IRW Press |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,2500 | +50,00 | |
| 1,9100 | +46,92 | |
| 0,9899 | +41,41 | |
| 0,6050 | +35,65 | |
| 8,6900 | +33,90 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9220 | -16,56 | |
| 6,1575 | -17,52 | |
| 6,6160 | -18,46 | |
| 1,7601 | -29,31 | |
| 1,1300 | -46,19 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 75.852.974 von J285607 am 28.05.24 17:12:18Grüße an die Tele Gruppe
. Die CEO hat zum Thema " Blackout " geantwortet( bissel Druck hilft ab und an)
Deshalb ein strong Dyor
. Die CEO hat zum Thema " Blackout " geantwortet( bissel Druck hilft ab und an)Deshalb ein strong Dyor
Zitat von wallander08: 1.2 oder 3 % vom Nettogehalt.....damit man in Deutschland beruhigt ist,....
Ich habe auch meine Zweifel dass sich das Management aktuell noch in einer Blackout befindet. Denke eher, dass uns da eine KE bevorsteht und die Dame daher aktuell nicht kauft!!
Antwort auf Beitrag Nr.: 75.852.461 von marvessa am 28.05.24 16:06:261.2 oder 3 % vom Nettogehalt.....damit man in Deutschland beruhigt ist,.... Hoffe die Dame shoppt mal richtig, günstig genus ist es ja in der Monatelangen(wers glaubt)" blackout period" geworden.📉💸
Hoffe die Dame shoppt mal richtig, günstig genus ist es ja in der Monatelangen(wers glaubt)" blackout period" geworden.📉💸
Antwort auf Beitrag Nr.: 75.852.410 von XC_2011 am 28.05.24 15:58:54Wird sie , zu 100 Prozent bin ich mir sicher
Antwort auf Beitrag Nr.: 75.851.096 von marvessa am 28.05.24 12:33:07
Ob sie kauft wird sich dann zeigen!
Zitat von marvessa: Wann ist black period zu Ende damit Cathy kaufen darf ?
Ob sie kauft wird sich dann zeigen!
Trading Spotlight
Black periode ist für Aktionäre schon länger.....
Wann ist black period zu Ende damit Cathy kaufen darf ?
Press Release - May 28, 2024
Sernova Appoints Jonathan Rigby to its Board of Directors
Sernova Appoints Jonathan Rigby to its Board of Directors
LONDON, Ontario; BOSTON, Massachusetts – May 28, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, announces today that Jonathan Rigby will join Sernova’s Board of Directors effective immediately.
“We are excited to welcome Jonathan to Sernova’s Board of Directors. With more than 30 years of diverse experience across the biopharmaceutical landscape, Jonathan brings a track record of substantial contributions across our sector as a biotech CEO and Board member. He will both complement and augment the expertise and composition of our current Board,” said Cynthia Pussinen, Chief Executive Officer of Sernova. “We welcome Jonathan’s passion for improving the lives of patients and his guidance on accelerating delivery of our development programs.”
Mr. Rigby has a breadth of industry knowledge and productive experience having served as President and CEO of Revolo Biotherapeutics where he took the company through multiple financings and two Phase 2 clinical trials, as well as serving as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS), with an oversold IPO. Mr. Rigby served as the CEO for SteadyMed Therapeutics (NASDAQ: STDY), which he listed on Nasdaq prior to its acquisition by United Therapeutics (NASDAQ: UTHR), and was co-founder of Zogenix (NASDAQ:ZGNX), which was also acquired by UCB (Euronext: UCB) after completing a NASDAQ listing.
In addition, Mr. Rigby currently serves on the Board of Directors of cancer therapy company Oncolytics Biotech Inc. (NASDAQ: ONCY) and IM Therapeutics which is developing therapies for Type 1 diabetes (T1D). He is a past Board Member of Thermalin Inc., which engineered new forms of insulin to improve patient lives and outcomes for the treatment of T1D and was formerly on the board of Xeris Pharmaceuticals (NASDAQ: XERS) which developed and commercialised a therapy to treat T1D severe hypoglycemia. Mr. Rigby holds a degree in Biological Sciences from the University of Sheffield, UK, and has a Master of Business Administration degree from the University of Portsmouth, UK.
“As an individual with T1D, I am acutely aware of the challenges of living with this life changing condition and the need to effectively cure the disease. Given Sernova’s vision of a future where chronic conditions are no longer insurmountable obstacles, and their foundational work on delivering a ‘functional cure’ for T1D, I am especially excited to join the Board and work hard to progress the company forward. Sernova represents a new era of development for cell therapy treatments and I look forward to working with the Board and the leadership team in advancing Sernova’s groundbreaking technology and therapies,” said Mr. Rigby.
Sernova Appoints Jonathan Rigby to its Board of Directors
Sernova Appoints Jonathan Rigby to its Board of Directors
LONDON, Ontario; BOSTON, Massachusetts – May 28, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, announces today that Jonathan Rigby will join Sernova’s Board of Directors effective immediately.
“We are excited to welcome Jonathan to Sernova’s Board of Directors. With more than 30 years of diverse experience across the biopharmaceutical landscape, Jonathan brings a track record of substantial contributions across our sector as a biotech CEO and Board member. He will both complement and augment the expertise and composition of our current Board,” said Cynthia Pussinen, Chief Executive Officer of Sernova. “We welcome Jonathan’s passion for improving the lives of patients and his guidance on accelerating delivery of our development programs.”
Mr. Rigby has a breadth of industry knowledge and productive experience having served as President and CEO of Revolo Biotherapeutics where he took the company through multiple financings and two Phase 2 clinical trials, as well as serving as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS), with an oversold IPO. Mr. Rigby served as the CEO for SteadyMed Therapeutics (NASDAQ: STDY), which he listed on Nasdaq prior to its acquisition by United Therapeutics (NASDAQ: UTHR), and was co-founder of Zogenix (NASDAQ:ZGNX), which was also acquired by UCB (Euronext: UCB) after completing a NASDAQ listing.
In addition, Mr. Rigby currently serves on the Board of Directors of cancer therapy company Oncolytics Biotech Inc. (NASDAQ: ONCY) and IM Therapeutics which is developing therapies for Type 1 diabetes (T1D). He is a past Board Member of Thermalin Inc., which engineered new forms of insulin to improve patient lives and outcomes for the treatment of T1D and was formerly on the board of Xeris Pharmaceuticals (NASDAQ: XERS) which developed and commercialised a therapy to treat T1D severe hypoglycemia. Mr. Rigby holds a degree in Biological Sciences from the University of Sheffield, UK, and has a Master of Business Administration degree from the University of Portsmouth, UK.
“As an individual with T1D, I am acutely aware of the challenges of living with this life changing condition and the need to effectively cure the disease. Given Sernova’s vision of a future where chronic conditions are no longer insurmountable obstacles, and their foundational work on delivering a ‘functional cure’ for T1D, I am especially excited to join the Board and work hard to progress the company forward. Sernova represents a new era of development for cell therapy treatments and I look forward to working with the Board and the leadership team in advancing Sernova’s groundbreaking technology and therapies,” said Mr. Rigby.
Durchsuchen
Sernova – Patentierte Zelltaschen mit Schutzschild gegen die Immunabwehr !
